Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104

Trial Profile

Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Dec 2018

At a glance

  • Drugs C2N 8E12 (Primary)
  • Indications Progressive supranuclear palsy
  • Focus Adverse reactions
  • Sponsors AbbVie
  • Most Recent Events

    • 07 Dec 2018 Planned End Date changed from 19 Oct 2020 to 13 Nov 2020.
    • 23 Jul 2018 Status changed from recruiting to active, no longer recruiting.
    • 04 May 2018 Planned number of patients changed from 10 to 5.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top